In stock COA-35%
In stock COA DOCUMENT SLOT-35%
Metabolic ResearchVK2735
Next-generation dual GLP-1/GIP receptor agonist by Viking Therapeutics — studied for superior appetite suppression and metabolic regulation.
Research catalogueLaboratory-use positioning
Batch documentationBatch certificate supplied with order
Order trackingFrom payment to dispatch
Product information
CompoundVK2735
Presentation5mg vial
CategoryMetabolic Research
AvailabilityIn stock
Batch COACertificate supplied with order
You save €157.00 on this presentation — an extra 10% off when you pay with crypto.
For research use only. Not for human consumption, diagnostic, therapeutic or veterinary use.
Overview
VK2735 is a novel dual GLP-1/GIP receptor agonist developed by Viking Therapeutics, currently in advanced clinical trials for obesity and metabolic disorders. Phase 2 data demonstrated average weight loss of 14.7% with the injectable form and 12.2% with the oral tablet over a short trial period — positioning it among the most potent metabolic research compounds in development. VK2735 targets both incretin receptor pathways simultaneously, building on the dual-agonist approach pioneered by tirzepatide with potential pharmacokinetic improvements.
Mechanism of Action
VK2735 activates two key incretin receptors: GLP-1R and GIPR. GLP-1 receptor agonism suppresses appetite via hypothalamic POMC/CART neuron activation, delays gastric emptying, and enhances glucose-dependent insulin secretion. Concurrent GIP receptor activation modulates adipose tissue function and may enhance central satiety signalling through complementary hypothalamic pathways. The dual mechanism produces synergistic metabolic effects — greater appetite suppression, improved glucose disposal, and enhanced energy expenditure — beyond what either receptor pathway achieves alone.
Research Applications
- Dual incretin receptor pharmacology and signalling research
- Next-generation obesity compound comparative studies
- Appetite regulation and hypothalamic pathway investigation
- Glucose homeostasis and insulin sensitivity models
- GLP-1/GIP receptor crosstalk and synergy research
FREE TOOL
Reconstitution calculator
Enter your reconstitution to get the draw volume for VK2735.
Concentration2.50 mg/ml
Draw volume0.100 ml
On the syringe10.0 units
Doses per vial20
10units
Pull the plunger to 10.0 units on a 1 ml U‑100 syringe0.100 ml · 2.50 mg/ml · 20 doses per vial
Concentration = peptide mass ÷ water volume. Unit readings assume U-100 insulin syringes, graduated 100 units per millilitre. For laboratory calculation only — not dosing guidance.